Subscribe to our newsletter to receive the latest product updates and special offers

HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite
Theme 		Help

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Earnings

Review historical estimates and see whether a company has beaten or missed expectations.

Open in Screener

PMN

ProMIS Neurosciences Inc.

Last Close
Jun 18 • 01:05PM ET
1.52
Dollar change
0.00
Percentage change
0.00 		%
Index- P/E- EPS (ttm)-0.84 Insider Own24.11% Shs Outstand18.89M Perf Week-11.11%
Market Cap28.82M Forward P/E- EPS next Y-0.56 Insider Trans0.00% Shs Float14.39M Perf Month-17.62%
Income-11.89M PEG- EPS next Q-0.14 Inst Own12.30% Short Float0.05% Perf Quarter-22.45%
Sales0.00M P/S- EPS this Y43.46% Inst Trans- Short Ratio0.65 Perf Half Y37.25%
Book/sh0.00 P/B373.46 EPS next Y7.44% ROA-298.08% Short Interest0.01M Perf Year-68.66%
Cash/sh0.13 P/C11.39 EPS next 5Y- ROE-1098.51% 52W Range0.95 - 8.95 Perf YTD32.17%
Dividend Est.- P/FCF- EPS past 5Y11.39% ROI-15419.32% 52W High-83.02% Beta0.66
Dividend TTM- Quick Ratio1.34 Sales past 5Y18.85% Gross Margin- 52W Low60.00% ATR (14)0.16
Dividend Ex-Date- Current Ratio1.34 EPS Y/Y TTM68.98% Oper. Margin0.00% RSI (14)37.17 Volatility5.17% 10.44%
Employees7 Debt/Eq0.00 Sales Y/Y TTM-100.00% Profit Margin- Recom1.00 Target Price8.75
Option/ShortNo / Yes LT Debt/Eq0.00 EPS Q/Q67.81% Payout- Rel Volume0.28 Prev Close1.52
Sales Surprise- EPS Surprise- Sales Q/Q- EarningsMay 14 AMC Avg Volume10.06K Price1.52
SMA20-10.91% SMA50-20.05% SMA200-16.11% Trades Volume1,986 Change0.00%
May-15-24 09:54AM
PMN Stock Earnings: ProMIS Neurosciences Beats EPS for Q1 2024
(InvestorPlace) -7.22%
May-14-24 04:01PM
ProMIS Neurosciences Announces First Quarter 2024 Financial Results and Recent Highlights
(GlobeNewswire)
Apr-30-24 07:00AM
ProMIS Neurosciences Publishes Study Highlighting Oligomer Selectivity and Benefit of Amyloid-Beta-Directed Antibodies
(GlobeNewswire)
Apr-09-24 07:00AM
ProMIS Neurosciences Publishes in the Journal of Biological Chemistry on the Interaction Between Pathogenic Proteins as a Treatment Target for ALS
(GlobeNewswire)
Apr-04-24 07:00AM
ProMIS Neurosciences to Present in Upcoming Investor Conferences in April
(GlobeNewswire)
10:53PM Loading…
Apr-01-24 10:53PM
PMN Stock Earnings: ProMIS Neurosciences Beats EPS for Q4 2023
(InvestorPlace) +7.33% +10.15%
04:15PM
ProMIS Neurosciences Announces Full Year 2023 Financial Results and Recent Highlights
(GlobeNewswire)
Mar-11-24 07:00AM
ProMIS Neurosciences Strengthens Global Intellectual Property Portfolio
(GlobeNewswire)
Feb-22-24 07:00AM
ProMIS Neurosciences to Present at the 2024 BIO CEO & Investor Conference
(GlobeNewswire) -10.14%
Jan-22-24 07:00AM
ProMIS Neurosciences Achieves Milestone in Development of Therapeutic Alpha-Synuclein Vaccine
(GlobeNewswire) +7.24%
Jan-08-24 07:00AM
ProMIS Neurosciences Issues Letter to Shareholders
(GlobeNewswire) +5.45%
Jan-03-24 07:00AM
ProMIS Neurosciences, Inc. Announces Leadership Transition
(GlobeNewswire) -7.82%
Dec-20-23 07:00AM
ProMIS Neurosciences Announces Publication on Novel Target for ALS
(GlobeNewswire)
Nov-20-23 07:00AM
ProMIS Neurosciences Doses First Subjects in Phase 1a Clinical Trial of PMN310 to Treat Alzheimer's Disease
(GlobeNewswire) +6.67%
Nov-14-23 04:30PM
ProMIS Neurosciences Announces Third Quarter 2023 Financial Results and Recent Highlights
(GlobeNewswire) -12.22% +9.36%
07:00AM Loading…
Sep-08-23 07:00AM
ProMIS Neurosciences Closes $20.4 Million Private Placement Financing
(GlobeNewswire)
Sep-06-23 12:18PM
ProMIS Neurosciences to Present at the H.C. Wainwright 25th Annual Global Investment Conference
(GlobeNewswire)
Aug-21-23 04:12PM
ProMIS Neurosciences Announces $20.4 Million Private Placement Financing
(GlobeNewswire) -9.14% +20.75%
Aug-14-23 05:33PM
ProMIS Neurosciences Announces Second Quarter 2023 Financial Results and Recent Highlights
(GlobeNewswire) -8.33%
Jul-17-23 07:00AM
ProMIS Showcases Preclinical Data at the Alzheimers Association International Conference 2023 on Computationally-Derived Antibody and Vaccine from Alzheimers Pipeline
(GlobeNewswire) +120.28%
Jul-14-23 07:45AM
ProMIS Announces Completion of Continuance
(GlobeNewswire)
Jul-10-23 07:55AM
ProMIS Neurosciences to Consolidate Trading on the Nasdaq Exchange
(GlobeNewswire) -8.11%
Jun-30-23 08:00AM
ProMIS Neurosciences Holds Annual Meeting of Shareholders All Resolutions Approved
(GlobeNewswire)
Jun-29-23 08:00AM
CORRECTION: Updated URL to Access ProMIS Annual Meeting of Shareholders on June 29, 2023 at 9:30am Eastern Time
(GlobeNewswire)
May-15-23 05:00PM
ProMIS Neurosciences Announces First Quarter 2023 Financial Results and Recent Highlights
(GlobeNewswire) -8.16%
May-08-23 09:00AM
ProMIS Neurosciences Announces FDA Clearance of Investigational New Drug (IND) Application for PMN310 in Alzheimers Disease
(GlobeNewswire)
Apr-25-23 05:00PM
Data Presented at American Academy of Neurology Annual Meeting on Novel Vaccine Design for Alzheimers Disease
(GlobeNewswire)
Apr-24-23 07:30AM
ProMIS Neurosciences Presents Preclinical Data Highlighting Targeting of Toxic Misfolded Proteins in Alzheimers Disease and ALS at American Academy of Neurology Annual Meeting
(GlobeNewswire) +8.31%
Apr-10-23 07:30AM
ProMIS Neurosciences Announces Submission of Investigational New Drug (IND) Application for Lead Antibody PMN310
(GlobeNewswire)
Mar-29-23 08:30AM
Lead Therapeutic Candidate, PMN310, Demonstrates Enhanced Selectivity for Toxic Oligomers Compared to Other Amyloid-Beta-Directed Antibodies in Poster Presentation at AD/PD 2023
(GlobeNewswire)
ProMIS Neurosciences, Inc. engages in the discovery and development of precision medicine solutions for early detection and effective treatment of neurodegenerative diseases. It focuses on the progression of Alzheimer's disease, amyotrophic lateral sclerosis, and Parkinson's disease. The company was founded by Neil Cashman and Vigen Nazarian on January 23, 2004 and is headquartered in Toronto, Canada.
open in screener | open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR
Open in Screener

DRRX

Durect Corp

Last Close
Jun 18 • 02:01PM ET
1.62
Dollar change
-0.16
Percentage change
-8.99 		%
Held by: VTI VXF IWC
Index- P/E- EPS (ttm)-1.00 Insider Own6.03% Shs Outstand30.33M Perf Week11.72%
Market Cap50.28M Forward P/E- EPS next Y-0.95 Insider Trans0.00% Shs Float29.17M Perf Month74.19%
Income-23.28M PEG- EPS next Q-0.16 Inst Own22.32% Short Float3.61% Perf Quarter37.29%
Sales8.32M P/S6.04 EPS this Y32.22% Inst Trans-3.45% Short Ratio6.32 Perf Half Y174.53%
Book/sh0.27 P/B6.06 EPS next Y-16.80% ROA-49.23% Short Interest1.05M Perf Year-70.76%
Cash/sh0.69 P/C2.35 EPS next 5Y15.00% ROE-196.94% 52W Range0.47 - 5.62 Perf YTD174.58%
Dividend Est.- P/FCF- EPS past 5Y5.33% ROI-216.24% 52W High-71.15% Beta1.08
Dividend TTM- Quick Ratio0.96 Sales past 5Y-3.23% Gross Margin82.49% 52W Low244.46% ATR (14)0.16
Dividend Ex-Date- Current Ratio1.05 EPS Y/Y TTM45.21% Oper. Margin-379.51% RSI (14)58.97 Volatility10.18% 13.41%
Employees58 Debt/Eq2.21 Sales Y/Y TTM-57.16% Profit Margin-279.77% Recom1.67 Target Price6.75
Option/ShortYes / Yes LT Debt/Eq0.30 EPS Q/Q50.54% Payout- Rel Volume1.35 Prev Close1.78
Sales Surprise-32.95% EPS Surprise-21.95% Sales Q/Q-11.05% EarningsMay 13 AMC Avg Volume166.62K Price1.62
SMA2011.19% SMA5041.15% SMA20021.34% Trades Volume159,674 Change-8.99%
Date Action Analyst Rating Change Price Target Change
Oct-30-20Initiated Chardan Capital Markets Buy $7
Oct-12-20Initiated ROTH Capital Buy
Jul-31-20Initiated Oppenheimer Outperform $7
Jan-31-20Initiated B. Riley FBR Buy $5
Nov-18-19Resumed Cantor Fitzgerald Overweight
Sep-06-19Initiated Cantor Fitzgerald Overweight $5
Mar-06-18Upgrade H.C. Wainwright Neutral → Buy $3.50
Oct-20-17Reiterated Laidlaw Buy $3 → $2
Oct-20-17Downgrade Stifel Buy → Hold $3 → $0.90
Oct-20-17Downgrade H.C. Wainwright Buy → Neutral
Show Previous Ratings
May-21-24 11:17AM
Durect Gets FDA Breakthrough Therapy Designation for Alcohol-Related Hepatitis Treatment
(MT Newswires) +24.04%
08:00AM
DURECT Corporation Receives FDA Breakthrough Therapy Designation for Larsucosterol in Alcohol-Associated Hepatitis
(PR Newswire)
May-14-24 01:21PM
Durect Far From Earnings Story But FDA Commentary Shows Path Forward, Oppenheimer Says
(MT Newswires) -14.02%
11:44AM
Q1 2024 DURECT Corp Earnings Call
(Thomson Reuters StreetEvents)
08:20AM
DURECT Corporation (NASDAQ:DRRX) Q1 2024 Earnings Call Transcript
(Insider Monkey)
03:03AM Loading…
03:03AM
Durect Corp (DRRX) Q1 2024 Earnings Call Transcript Highlights: Navigating Financial Challenges ...
(GuruFocus.com)
May-13-24 08:54PM
DRRX Stock Earnings: Durect Misses EPS, Misses Revenue for Q1 2024
(InvestorPlace)
05:20PM
Durect (DRRX) Reports Q1 Loss, Misses Revenue Estimates
(Zacks)
04:17PM
Durect: Q1 Earnings Snapshot
(Associated Press Finance)
04:05PM
DURECT Corporation Reports First Quarter 2024 Financial Results and Business Update
(PR Newswire)
May-07-24 04:30PM
DURECT Corporation to Announce First Quarter 2024 Financial Results and Provide a Business Update
(PR Newswire) -15.00%
Apr-30-24 07:00AM
DURECT Corporation Announces Late-Breaking Oral Presentation at the EASL Congress 2024 to Discuss AHFIRM Phase 2b Data in Alcohol-Associated Hepatitis
(PR Newswire)
Apr-01-24 02:11PM
DURECT Corporation (NASDAQ:DRRX) Q4 2023 Earnings Call Transcript
(Insider Monkey) -8.26%
Mar-27-24 08:53PM
DRRX Stock Earnings: Durect Beats EPS, Beats Revenue for Q4 2023
(InvestorPlace) +5.51% -9.70%
05:10PM
Durect (DRRX) Reports Q4 Loss, Misses Revenue Estimates
(Zacks)
04:19PM Loading…
04:19PM
Durect: Q4 Earnings Snapshot
(Associated Press Finance)
04:01PM
DURECT Corporation Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
(PR Newswire)
Mar-20-24 04:30PM
DURECT Corporation to Announce Fourth Quarter and Full Year 2023 Financial Results and Provide a Business Update
(PR Newswire) +8.47%
Mar-04-24 07:00AM
DURECT and Charles River Laboratories Enter into Co-Marketing and Collaboration Agreement for ALZET Product Line in U.S. and Canada
(PR Newswire)
Feb-07-24 06:48PM
DURECT Corporation to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
(PR Newswire) -6.69% +7.08%
Nov-14-23 08:05AM
Q3 2023 DURECT Corp Earnings Call
(Thomson Reuters StreetEvents)
Nov-13-23 04:40PM
Durect: Q3 Earnings Snapshot
(Associated Press Finance)
04:05PM
DURECT Corporation Reports Third Quarter 2023 Financial Results and Business Update
(PR Newswire)
Nov-09-23 04:30PM
DURECT Corporation to Announce Third Quarter 2023 Financial Results and Provide a Business Update
(PR Newswire) +8.29% -7.06%
Nov-08-23 08:40AM
Why Is Durect (DRRX) Stock Down 64% Today?
(InvestorPlace) -79.57%
07:59AM
Durect fails alcohol-associated hepatitis trial, plans phase 3 anyway as investors scorch stock
(FierceBiotech.com)
Nov-07-23 04:01PM
DURECT Corporation Announces Topline Results from Phase 2b AHFIRM Trial of Larsucosterol in Alcohol-Associated Hepatitis with Promising Effect on Mortality
(PR Newswire)
Oct-19-23 10:44AM
These 2 Strong Buy Penny Stocks Have Massive Upside Potential, Says Oppenheimer
(TipRanks) +12.31%
Oct-02-23 03:07PM
3 Promising Biotech Stocks That Will Make Early Investors Rich
(InvestorPlace)
Sep-07-23 07:00AM
DURECT Corporation Announces Last Patient Last Visit in Phase 2b AHFIRM Trial of Larsucosterol in Alcohol-Associated Hepatitis
(PR Newswire)
04:30PM Loading…
Aug-31-23 04:30PM
DURECT Corporation Announces Presentations in Upcoming Investor Conferences
(PR Newswire)
Aug-14-23 07:55AM
10 Oversold Penny Stocks To Buy
(Insider Monkey)
Aug-10-23 07:08AM
Q2 2023 DURECT Corp Earnings Call
(Thomson Reuters StreetEvents)
Aug-09-23 05:50PM
Durect (DRRX) Reports Q2 Loss, Misses Revenue Estimates
(Zacks)
04:43PM
Durect: Q2 Earnings Snapshot
(Associated Press Finance)
04:05PM
DURECT Corporation Reports Second Quarter 2023 Financial Results and Business Update
(PR Newswire)
Aug-03-23 04:30PM
DURECT Corporation to Announce Second Quarter 2023 Financial Results and Provide a Business Update
(PR Newswire)
Jul-28-23 04:19PM
10 Best Rated Penny Stocks to Buy According to Analysts
(Insider Monkey) +8.52%
Jul-20-23 08:00AM
DURECT Corporation Announces $15 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
(PR Newswire) -33.13%
Jun-07-23 06:00AM
DURECT Completes Enrollment in Phase 2b AHFIRM Trial of Larsucosterol in Alcohol-Associated Hepatitis
(PR Newswire)
May-11-23 09:55AM
Wall Street Analysts Think Durect (DRRX) Could Surge 594.98%: Read This Before Placing a Bet
(Zacks)
May-08-23 05:25PM
Durect (DRRX) Reports Q1 Loss, Misses Revenue Estimates
(Zacks) +10.60%
04:23PM
Durect: Q1 Earnings Snapshot
(AP Finance)
04:05PM
DURECT Corporation Reports First Quarter 2023 Financial Results and Business Update
(PR Newswire)
May-01-23 07:03PM
DURECT Corporation to Announce First Quarter 2023 Financial Results and Provide Business Update on May 8
(PR Newswire)
Apr-27-23 05:11PM
DURECT Corporation to Host KOL Event on Alcohol-Associated Hepatitis
(PR Newswire)
Apr-25-23 06:45PM
DURECT Corporation to Participate in Fireside Chat at the H.C. Wainwright BioConnect Investor Conference
(PR Newswire)
Apr-10-23 06:00AM
DURECT Announces Peer-Reviewed Article Accepted for Publication with Additional Data from Previously Completed Phase 2a Study of Larsucosterol in Alcohol-Associated Hepatitis
(PR Newswire)
Mar-24-23 06:30AM
7 Biotech Stocks Sitting in the Sweet Spot
(InvestorPlace)
Mar-21-23 04:30PM
DURECT Corporation Announces Appointment of Gail Maderis as Chair of the Board
(PR Newswire)
Mar-11-23 07:33AM
DURECT Corporation (NASDAQ:DRRX) Q4 2022 Earnings Call Transcript
(Insider Monkey)
Mar-09-23 08:30AM
DURECT Corporation Fireside Chat at the Oppenheimer 33rd Annual Healthcare Conference
(PR Newswire)
Mar-08-23 05:53AM
Q4 2022 DURECT Corp Earnings Call
(Thomson Reuters StreetEvents)
Mar-07-23 05:35PM
Durect (DRRX) Reports Q4 Loss, Tops Revenue Estimates
(Zacks)
04:05PM
DURECT Corporation Reports Fourth Quarter and Full Year 2022 Financial Results and AHFIRM Trial Update
(PR Newswire)
Feb-28-23 06:07PM
DURECT Corporation to Announce Fourth Quarter and Full Year 2022 Financial Results and Provide Business Update on March 7
(PR Newswire)
Feb-17-23 06:30AM
7 Stocks Under $10 to Buy in February
(InvestorPlace)
Feb-03-23 05:17PM
DURECT Corporation Announces $10 Million Registered Direct Offering of Common Stock and Warrants
(PR Newswire) -9.38%
Jan-11-23 07:59AM
Durect (DRRX) Soars 11.8%: Is Further Upside Left in the Stock?
(Zacks)
Nov-28-22 06:46PM
DURECT Announces 1-for-10 Reverse Stock Split
(PR Newswire) -11.24%
Nov-02-22 06:05PM
Durect (DRRX) Reports Q3 Loss, Misses Revenue Estimates
(Zacks) -8.89%
04:05PM
DURECT Corporation Reports Third Quarter 2022 Financial Results and Update of Programs
(PR Newswire)
Oct-26-22 08:30AM
DURECT Corporation to Announce Third Quarter 2022 Financial Results and Provide Business Update on November 2
(PR Newswire)
Oct-06-22 08:30AM
DURECT Reaches Enrollment Milestone in Phase 2b AHFIRM Trial
(PR Newswire)
Sep-26-22 08:30AM
Innocoll and DURECT Announce U.S. launch of POSIMIR®
(PR Newswire) +11.20%
Sep-06-22 08:00AM
DURECT Corporation to Present at the H.C. Wainwright Global Investment Conference
(PR Newswire) -8.40%
Aug-08-22 06:09AM
Rainbows and Unicorns: DURECT Corporation (NASDAQ:DRRX) Analysts Just Became A Lot More Optimistic
(Simply Wall St.) +6.58%
Aug-04-22 07:35PM
Durect (DRRX) Reports Q2 Loss, Lags Revenue Estimates
(Zacks) +7.12%
04:05PM
DURECT Corporation Reports Second Quarter 2022 Financial Results and Update of Programs
(PR Newswire)
Jul-27-22 04:15PM
DURECT Corporation to Announce Second Quarter 2022 Financial Results and Provide Business Update on August 4
(PR Newswire)
Jul-24-22 08:41AM
6 Penny Stocks With 1,000% Upside Potential
(InvestorPlace)
Jul-15-22 06:15AM
Shareholders in DURECT (NASDAQ:DRRX) are in the red if they invested five years ago
(Simply Wall St.)
Jul-05-22 08:30AM
DURECT Corporation Appoints Timothy M. Papp as Chief Financial Officer
(PR Newswire)
Jun-18-22 08:05AM
What Kind Of Shareholders Hold The Majority In DURECT Corporation's (NASDAQ:DRRX) Shares?
(Simply Wall St.)
May-31-22 06:21AM
Health Check: How Prudently Does DURECT (NASDAQ:DRRX) Use Debt?
(Simply Wall St.) +32.08%
May-18-22 01:53PM
DURECT Corporation to Present at the H.C. Wainwright Global Investment Conference
(PR Newswire)
May-08-22 08:19AM
DURECT Corporation (NASDAQ:DRRX) Just Reported Earnings, And Analysts Cut Their Target Price
(Simply Wall St.)
May-04-22 06:25PM
Durect (DRRX) Reports Q1 Loss, Lags Revenue Estimates
(Zacks) +12.70% -7.59%
04:05PM
DURECT Corporation Reports First Quarter 2022 Financial Results and Update of Programs
(PR Newswire)
Apr-27-22 04:15PM
DURECT Corporation to Announce First Quarter 2022 Financial Results and Provide Business Update on May 4
(PR Newswire) +13.17%
Mar-24-22 09:30AM
Alpine Immune Sciences, Inc. (ALPN) Soars 6%: Is Further Upside Left in the Stock?
(Zacks)
Mar-23-22 04:15PM
DURECT Corporation To Present at the 2022 Cantor Fitzgerald Virtual Rare Orphan Disease Summit
(PR Newswire) -5.54%
01:29PM
As DURECT Corporation's (NASDAQ:DRRX) market cap increased US$26m, insiders who bought last year may be reflecting on buying more
(Simply Wall St.)
Mar-09-22 04:30PM
DURECT Corporation Fireside Chat at the Oppenheimer 32nd Annual Healthcare Conference
(PR Newswire) +10.00% -6.06%
Mar-07-22 05:25PM
Durect (DRRX) Reports Q4 Loss, Tops Revenue Estimates
(Zacks) -5.71%
04:05PM
DURECT Corporation Reports Fourth Quarter and Full Year 2021 Financial Results and Update of Programs
(PR Newswire)
Mar-01-22 08:30AM
DURECT Corporation Doses First European Patient in Phase 2b AHFIRM Study of Larsucosterol(DUR-928) in Severe Alcohol-Associated Hepatitis
(PR Newswire)
Feb-28-22 04:30PM
DURECT Corporation to Announce Fourth Quarter and Full Year 2021 Financial Results and Provide Business Update on March 7
(PR Newswire)
09:15AM
Zogenix (ZGNX) Reports Q4 Loss, Tops Revenue Estimates
(Zacks)
Jan-13-22 10:00AM
Here's Why Durect (DRRX) is Poised for a Turnaround After Losing 17.1% in 4 Weeks
(Zacks)
Jan-06-22 04:05PM
DURECT Corporation to Participate in H.C. Wainwright Bioconnect Conference
(PR Newswire)
Dec-22-21 07:30AM
DURECT and Innocoll Announce a $136 Million U.S. Licensing Agreement for POSIMIR® (Bupivacaine Solution)
(PR Newswire)
05:45AM
Do Institutions Own DURECT Corporation (NASDAQ:DRRX) Shares?
(Simply Wall St.)
Dec-14-21 09:00AM
DURECT Corporation Expands Board of Directors with Appointment of Biopharmaceutical Industry Finance Veteran Peter Garcia
(PR Newswire)
Nov-29-21 09:00AM
DURECT Corporation to Participate in Alcoholic Liver Disease Workshop Today at the 5th Annual NASH Summit
(PR Newswire)
Nov-12-21 09:00AM
Data Presentation Today at The Liver Meeting® 2021 Shows Increasing Hospital Admissions for Alcohol-Associated Hepatitis (AH) in the U.S.
(PR Newswire) -6.40%
Nov-10-21 09:00AM
DURECT Corporation Doses First ex-U.S. Patient in Phase 2b AHFIRM Study of Larsucosterol (DUR-928) in Severe Alcohol-Associated Hepatitis
(PR Newswire)
Nov-08-21 09:00AM
DURECT Corporation Announces Poster Presentation on the Prevalence of Hospitalized Alcohol-Associated Hepatitis (AH) Patients in the U.S. to be Presented at The Liver Meeting® 2021
(PR Newswire)
Nov-07-21 07:45AM
Health Check: How Prudently Does DURECT (NASDAQ:DRRX) Use Debt?
(Simply Wall St.)
Nov-02-21 06:15PM
Durect (DRRX) Reports Q3 Loss, Misses Revenue Estimates
(Zacks)
DURECT Corp. focuses on advancing novel and potentially lifesaving investigational therapies derived from its Epigenetic Regulator Program. Its pipeline is called DUR-928, an endogenous sulfated oxysterol and an epigenetic regulator. The company was founded by James E. Brown and Felix Theeuwes on February 6, 1998 and is headquartered in Cupertino, CA.
open in screener | open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR
affiliate • advertise • toggle light mode • contact • privacy • help
do not sell my data • privacy settings
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2024 FINVIZ.com. All Rights Reserved.